BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 29893854)

  • 1. Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting.
    Williams ET; Glauser L; Tsika E; Jiang H; Islam S; Moore DJ
    Hum Mol Genet; 2018 Sep; 27(18):3189-3205. PubMed ID: 29893854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.
    Tsika E; Glauser L; Moser R; Fiser A; Daniel G; Sheerin UM; Lees A; Troncoso JC; Lewis PA; Bandopadhyay R; Schneider BL; Moore DJ
    Hum Mol Genet; 2014 Sep; 23(17):4621-38. PubMed ID: 24740878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation in VPS35 associated with Parkinson's disease impairs WASH complex association and inhibits autophagy.
    Zavodszky E; Seaman MN; Moreau K; Jimenez-Sanchez M; Breusegem SY; Harbour ME; Rubinsztein DC
    Nat Commun; 2014 May; 5():3828. PubMed ID: 24819384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer.
    Follett J; Norwood SJ; Hamilton NA; Mohan M; Kovtun O; Tay S; Zhe Y; Wood SA; Mellick GD; Silburn PA; Collins BM; Bugarcic A; Teasdale RD
    Traffic; 2014 Feb; 15(2):230-44. PubMed ID: 24152121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VPS35 pathogenic mutations confer no dominant toxicity but partial loss of function in Drosophila and genetically interact with parkin.
    Malik BR; Godena VK; Whitworth AJ
    Hum Mol Genet; 2015 Nov; 24(21):6106-17. PubMed ID: 26251041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease-linked
    Chen X; Kordich JK; Williams ET; Levine N; Cole-Strauss A; Marshall L; Labrie V; Ma J; Lipton JW; Moore DJ
    Proc Natl Acad Sci U S A; 2019 Mar; 116(12):5765-5774. PubMed ID: 30842285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of VPS35 in the Pathobiology of Parkinson's Disease.
    Sassone J; Reale C; Dati G; Regoni M; Pellecchia MT; Garavaglia B
    Cell Mol Neurobiol; 2021 Mar; 41(2):199-227. PubMed ID: 32323152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VPS35, the Retromer Complex and Parkinson's Disease.
    Williams ET; Chen X; Moore DJ
    J Parkinsons Dis; 2017; 7(2):219-233. PubMed ID: 28222538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. VPS35 and retromer dysfunction in Parkinson's disease.
    Rowlands J; Moore DJ
    Philos Trans R Soc Lond B Biol Sci; 2024 Apr; 379(1899):20220384. PubMed ID: 38368930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson's disease.
    Chen X; Tsika E; Levine N; Moore DJ
    Mol Neurodegener; 2023 Aug; 18(1):51. PubMed ID: 37542299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of
    Sargent D; Moore DJ
    Int Rev Mov Disord; 2021; 2():221-244. PubMed ID: 35497708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VPS35 in Dopamine Neurons Is Required for Endosome-to-Golgi Retrieval of Lamp2a, a Receptor of Chaperone-Mediated Autophagy That Is Critical for α-Synuclein Degradation and Prevention of Pathogenesis of Parkinson's Disease.
    Tang FL; Erion JR; Tian Y; Liu W; Yin DM; Ye J; Tang B; Mei L; Xiong WC
    J Neurosci; 2015 Jul; 35(29):10613-28. PubMed ID: 26203154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endosomal dysfunction in iPSC-derived neural cells from Parkinson's disease patients with VPS35 D620N.
    Bono K; Hara-Miyauchi C; Sumi S; Oka H; Iguchi Y; Okano HJ
    Mol Brain; 2020 Oct; 13(1):137. PubMed ID: 33032646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parkinson's disease-associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy.
    Ma KY; Fokkens MR; Reggiori F; Mari M; Verbeek DS
    Transl Neurodegener; 2021 Jun; 10(1):19. PubMed ID: 34127073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. VPS35 regulates cell surface recycling and signaling of dopamine receptor D1.
    Wang C; Niu M; Zhou Z; Zheng X; Zhang L; Tian Y; Yu X; Bu G; Xu H; Ma Q; Zhang YW
    Neurobiol Aging; 2016 Oct; 46():22-31. PubMed ID: 27460146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N.
    Munsie LN; Milnerwood AJ; Seibler P; Beccano-Kelly DA; Tatarnikov I; Khinda J; Volta M; Kadgien C; Cao LP; Tapia L; Klein C; Farrer MJ
    Hum Mol Genet; 2015 Mar; 24(6):1691-703. PubMed ID: 25416282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the VPS35 D620N mutation in Parkinson's disease.
    Mohan M; Mellick GD
    Parkinsonism Relat Disord; 2017 Mar; 36():10-18. PubMed ID: 27964832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Formation of retromer transport carriers is disrupted by the Parkinson disease-linked Vps35 D620N variant.
    Cui Y; Yang Z; Flores-Rodriguez N; Follett J; Ariotti N; Wall AA; Parton RG; Teasdale RD
    Traffic; 2021 Apr; 22(4):123-136. PubMed ID: 33347683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on cellular and molecular determinants of Parkinson's disease with emphasis on the role of the retromer complex.
    Macías-Calvio V; Fuentealba LM; Marzolo MP
    J Neurosci Res; 2021 Jan; 99(1):163-179. PubMed ID: 32633426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VPS35 regulates parkin substrate AIMP2 toxicity by facilitating lysosomal clearance of AIMP2.
    Yun SP; Kim H; Ham S; Kwon SH; Lee GH; Shin JH; Lee SH; Ko HS; Lee Y
    Cell Death Dis; 2017 Apr; 8(4):e2741. PubMed ID: 28383562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.